Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Intra-Cellular Therapies (ITCI) PT Raised to $28 at SunTrust Robinson Humphrey; 'Adding Back Bipolar Depression'
March 2, 2018 9:03 AM ESTSunTrust Robinson Humphrey raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $28.00 (from $22.00) while maintaining a Buy rating.
Analyst Edward Nash commented, "Intra-Cellular will have a pre-NDA meeting with the FDA in 1Q18 for lumateperone for schizophrenia. Company expects to file NDA for... More
